Novel lipidic micro- and nanoformulations of doxorubicin: An updated review

Doxorubicin (Dox) is a common compound in chemotherapy. Dox inhibits the proliferation of cancer cells by affecting the replication mechanism. multidrug resistance (MDR), and dose-dependence and cardiotoxicity are its side effects. Scientists have developed lipid formulations at micro and nano scales to overcome these challenges. The first commercial Dox lipid formulation is Doxil ®. This up-to-date review summarizes and critically evaluates the latest developments (۲۰۲۰-۲۰۲۶) in various Dox lipid formulations. This product is somewhat successful in reducing Dox toxicity. A comprehensive search of PubMed, Web of Science, and clinical trial registries was performed, and studies that provide preclinical efficacy and safety data of lipid formulations were emphasized. Lipid nanocarriers such as SLNs and NLCs have not yet been commercialized, and studies in this field are limited. Future directions should prioritize combinations with immunotherapies and smart nanocarrier strategies to realize the full potential of next-generation "Dox" nanomedicines.

کلیدواژه ها:

doxorubicin ، Multidrug Resistance ، lipid formulations ، Chemotherapy